MedTrace Logo

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

NCT07298915 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-06

No results posted yet for this study

Summary

This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity.

The main questions it will answer includes:

* Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone
* Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life

Participants will:

* Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician
* (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training
* Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures

Conditions

  • Obesity & Overweight

Interventions

DRUG

Tirzepatide

Participants will take tirzepatide under the care of their primary care provider for 16 weeks

BEHAVIORAL

Exercise

Participants will perform a combination of aerobic and resistance training for 16 weeks

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Damon L Swift, Ph.D · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2026-12-31
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07298915 on ClinicalTrials.gov